In an interview with PharmaShots, Nirav Desai, Global Clinical Development Lead at Takeda shared his views on TAK-721 data presented at ACG 2020 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 years…
